Forecasting fortunes for US approval
This article was originally published in Scrip
Executive Summary
BioMedTracker’s Karen Nguyen looks at recent clinical developments in three key disease areas to assess the likelihood of approval (LOA) for the newest innovative drugs.
You may also be interested in...
Breaking Down FDA's Breakthrough Program – Infographic
A review of the impact FDA's newest expedited approval pathway has had on drug development and regulatory review, using data from Pink Sheet's FDA Performance Tracker, BioMedTracker and MedTrack.
ASCO Immunotherapy Alert: BioMedTracker’s Top Abstract Picks
With cancer checkpoint inhibitors extremely high on the radar at the upcoming American Society of Clinical Oncology annual meeting, BioMedTracker analysts identify the most compelling immunotherapy abstracts.